InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China



In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively. Read More



Source link

  • Related Posts

    Supreme Court hears arguments over birthright citizenship

    IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Supreme Court hears arguments over birthright citizenship 01:13 UP NEXT Megan Thee Stallion…

    Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill

    Eli Lilly stock (LLY) popped by more than 5% on Wednesday after the Food and Drug Administration (FDA) approved the company’s new weight-loss pill that Eli Lilly says can be…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Supreme Court hears arguments over birthright citizenship

    Supreme Court hears arguments over birthright citizenship

    Evacuated From War-Torn Gaza, 11 Toddlers Return Home to Hugs and Tears

    Georgia’s Brad Raffensperger showcases Ponzi scheme fight as he runs for governor

    Georgia’s Brad Raffensperger showcases Ponzi scheme fight as he runs for governor

    Hiker’s dog lost in forest rescued by helicopter after strangers fund search

    Hiker’s dog lost in forest rescued by helicopter after strangers fund search

    Today’s NYT Connections: Sports Edition Hints, Answers for April 1 #555

    Today’s NYT Connections: Sports Edition Hints, Answers for April 1 #555

    Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill

    Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill